✦Corporate brand & media services✦Made in Virginia Beach since 1997✦Boards engagement today people · AI✦
Old boatGrew revenue 110% in FY2025 to $53 million, operating margin -104% against a -15.8% median for biological products, (no diagnostic substances), equity 87.2% of assets.
Last filing10-Q, 16 Nov 2026
🫧 Edgar looked up INVIVYD, INC. ($IVVD). Last filing: 10-Q, 2026-11-16. 13 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $53.4M (FY2025). Experience: revenue up 110.5% on the year; operating margin -104.0%, up from -696.8%. Soundness: equity 87.2% of assets, return on equity -21.7%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $82.5M and $148.2M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -104.0% against a -15.8% median; growth 110.5% against 21.4%.
Read from its own SEC filings · nothing written, nothing inferred
| Cash flow (op · inv · fin · free) | −$58M · −$0M · $216M · −$58M |
| Investment book (cash · short · long) | $227M · — · — · current ratio 7.24 |
| Revenue swing · equity of assets | — · 87.2% |
| Fiscal year end | 2025-12-31 |
| Revenue | $53M |
| Revenue, on the year | 110.5% |
| Revenue, a year over the record | — |
| Operating margin | −104.0% |
| Operating margin, prior year | −696.8% |
| Net margin | −98.2% |
| Research and development | $38M · 71.7% of revenue |
| Total debt | — |
| Equity of assets | 87.2% |
| Return on equity | −21.7% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-0.3 |
| Book value per share | $1.40 |
| Revenue per share | $0.31 |
| Shares outstanding | 172,212,902 |
| Audited years read | 3 |
Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).
Classic signals · fiscal 2025Altman Z″ -0.36 distress zone 1968Piotroski F 3 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals 2.8% earnings backed by cash 1996DuPont ROE -34% = margin -98.2% × turns 0.26 × leverage 1.31
What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →
Health watch · 12 monthsExchange listing notice or transferDirector or officer change
Versus peersoperating margin −104.0% vs a −15.8% median · revenue growth 110.5% vs 21.4% · cash beats 8% of its size class · growth beats 95% 31 biological products filers
Trend · last year to this▲operating margin −696.8% → −104.0% · ▲revenue $25.4M → $53.4M
| # | Company | Condition | Operating margin | Revenue growth | Sales | |
|---|---|---|---|---|---|---|
| 1 | ![]() | ExelixisEXEL | New ship | 37.6% | 7.0% | $2.3B |
| 2 | ![]() | Halozyme TherapeuticsHALO | New ship | 33.6% | 37.6% | $1.4B |
| 3 | ![]() | Neurocrine BiosciencesNBIX | New ship | 21.6% | 21.4% | $2.9B |
| 4 | ![]() | VaxartVXRT | New ship | 7.6% | 726.7% | $237.3M |
| 5 | ![]() | Maze TherapeuticsMAZE | Sound ship | 34.4% | — | $167.5M |
| 6 | ![]() | AmgenAMGN | Sound ship | 24.7% | 10.0% | $36.8B |
| 7 | ![]() | RepligenRGEN | Sound ship | 7.5% | 16.4% | $738.3M |
| 8 | ![]() | ExozymesEXOZ | Sound ship | −2563.5% | — | $0.1M |
| 9 | ![]() | Lexeo TherapeuticsLXEO | Sound ship | −9252.1% | — | $0.7M |
| 10 | ![]() | Calidi BiotherapeuticsCLDI | Sound ship | −51395.6% | — | $0.0M |
| 11 | ![]() | Monte Rosa TherapeuticsGLUE | Weathered boat | −43.8% | 63.5% | $123.7M |
| 12 | ![]() | Alpha CognitionACOG | Weathered boat | −221.7% | — | $10.2M |
| 13 | ![]() | HumacyteHUMA | Weathered boat | −5306.0% | — | $2.0M |
| 14 | ![]() | Candel TherapeuticsCADL | Weathered boat | −27777.6% | 0.0% | $0.1M |
| 15 | ![]() | Revolution MedicinesRVMD | Weathered boat | — | — | $0.0M |
| 16 | ![]() | Scholar Rock HoldingSRRK | Weathered boat | — | −100.0% | $0.0M |
| 17 | ![]() | Allogene TherapeuticsALLO | Weathered boat | — | −100.0% | $0.0M |
| 18 | ![]() | Inhibikase TherapeuticsIKT | Weathered boat | — | −100.0% | $0.0M |
| 19 | ![]() | NKGen Biotech1845459 | Weathered boat | — | −100.0% | $0.0M |
| 20 | ![]() | Champions OncologyCSBR | Old boat | −1.9% | 4.4% | $59.4M |
| 21 | ![]() | Fennec PharmaceuticalsFENC | Old boat | −14.1% | −6.1% | $44.6M |
| 22 | ![]() | Tarsus PharmaceuticalsTARS | Old boat | −15.7% | 146.7% | $451.4M |
| 23 | ![]() | Century Therapeutics, Inc.IPSC | Old boat | −15.8% | 1556.8% | $109.2M |
| 24 | ![]() | CurisCRIS | Old boat | −60.5% | −13.4% | $9.4M |
| 25 | ![]() | RegenxbioRGNX | Old boat | −94.6% | 104.5% | $170.4M |
| 26 | ![]() | InvivydIVVD · this company | Old boat | −104.0% | 110.5% | $53.4M |
| 27 | ![]() | Pelthos TherapeuticsPTHS | Old boat | −193.1% | — | $16.8M |
| 28 | ![]() | Dyadic InternationalDYAI | Old boat | −232.8% | −11.6% | $3.1M |
| 29 | ![]() | X4 PharmaceuticalsXFOR | Old boat | −247.4% | 1250.5% | $35.1M |
| 30 | ![]() | Lenz TherapeuticsLENZ | Old boat | −477.5% | — | $19.1M |
| 31 | ![]() | AlectorALEC | Old boat | −741.3% | −79.1% | $21.0M |
| 32 | ![]() | Recursion PharmaceuticalsRXRX | Old boat | −867.9% | 26.9% | $74.7M |
| 33 | ![]() | Aligos TherapeuticsALGS | Old boat | −4024.9% | −39.5% | $2.2M |
| 34 | ![]() | Prime MedicinePRME | Old boat | −4498.1% | 55.3% | $4.6M |
| 35 | ![]() | Cardiff OncologyCRDF | Old boat | −8256.3% | −13.2% | $0.6M |
| 36 | ![]() | Inhibrx BiosciencesINBX | Old boat | −10386.5% | 550.0% | $1.3M |
| 37 | ![]() | Crispr Therapeutics AGCRSP | Old boat | −18933.6% | −90.6% | $3.5M |
| 38 | ![]() | Entera BioENTX | Old boat | −27450.0% | −76.8% | $0.0M |
| 39 | ![]() | BioatlaBCAB | Old boat | −32146.7% | — | $0.3M |
| 40 | ![]() | Atyr PharmaATYR | Old boat | −40856.3% | −19.1% | $0.2M |
| 41 | ![]() | Inmune BioINMB | Old boat | −94766.0% | 257.1% | $0.1M |
| 42 | ![]() | Creative Medical Technology HoldingsCELZ | Old boat | −102380.2% | −45.5% | $0.0M |
| 43 | ![]() | Senti Biosciences HoldingsSNTI | Old boat | −312631.8% | — | $0.0M |
| 44 | ![]() | Eloxx PharmaceuticalsELOX | Old boat | — | −100.0% | $0.0M |
| 45 | ![]() | Pharmacyte BiotechPMCB | Old boat | — | — | $0.0M |
| 46 | ![]() | Artiva BiotherapeuticsARTV | Old boat | — | −100.0% | $0.0M |
| 47 | ![]() | Zeo ScientifiXZEOX | Rotting at the dock | −103.6% | 12.5% | $5.2M |
| 48 | ![]() | MeiraGTx HoldingsMGTX | Rotting at the dock | −130.2% | 144.6% | $81.4M |
| 49 | ![]() | ModernaMRNA | Rotting at the dock | −158.1% | −39.9% | $1.9B |
| 50 | ![]() | Lineage Cell TherapeuticsLCTX | Rotting at the dock | −251.6% | 53.2% | $14.6M |
| 51 | ![]() | Sangamo TherapeuticsSGMOQ | Rotting at the dock | −306.5% | −31.6% | $39.6M |
| 52 | ![]() | Voyager TherapeuticsVYGR | Rotting at the dock | −326.6% | −49.5% | $40.4M |
| 53 | ![]() | Coherus Oncology, Inc.CHRS | Rotting at the dock | −429.5% | 59.8% | $42.2M |
| 54 | ![]() | Vir BiotechnologyVIR | Rotting at the dock | −699.2% | −7.6% | $68.6M |
| 55 | ![]() | Scilex Holding CompanySCLX | Rotting at the dock | −1143.7% | −46.5% | $30.3M |
| 56 | ![]() | Surrozen, Inc./DESRZN | Rotting at the dock | −1210.6% | −67.4% | $3.5M |
| 57 | ![]() | Tscan TherapeuticsTCRX | Rotting at the dock | −1315.4% | 266.7% | $10.3M |
| 58 | ![]() | Caribou BiosciencesCRBU | Rotting at the dock | −1329.4% | 11.7% | $11.2M |
| 59 | ![]() | OcugenOCGN | Rotting at the dock | −1425.7% | 8.8% | $4.4M |
| 60 | ![]() | Fate TherapeuticsFATE | Rotting at the dock | −2222.4% | −51.2% | $6.6M |
| 61 | ![]() | PluriPLUR | Rotting at the dock | −2454.5% | −24.0% | $1.0M |
| 62 | ![]() | Abpro HoldingsABPO | Rotting at the dock | −5421.3% | 50.0% | $0.2M |
| 63 | ![]() | VivoSim LabsVIVS | Rotting at the dock | −8768.7% | −9.0% | $0.1M |
| 64 | ![]() | Aim ImmunotechAIM | Rotting at the dock | −13254.5% | −48.2% | $0.1M |
| 65 | ![]() | ProKidneyPROK | Rotting at the dock | −18477.8% | 1075.0% | $0.9M |
From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.
Sailing speed follows growth: 110.5% a year crosses the harbor in 30 seconds.
🌊 Visit the Bay →Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·
Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time info@pops4.comNine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.